What can be concluded from the ERSPC and PLCO trial data?

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 6, 2010, Pages 668-669

  Studer, Urs E ^a   Collette, Laurence ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b Statistics Department   (Belgium)

Author keywords

Overdetection; Overtreatment; Prostate cancer; PSA screening

Indexed keywords

CANCER RISK; CANCER SCREENING; CLINICAL RESEARCH; CLINICAL TRIAL; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW;

CLINICAL TRIALS AS TOPIC; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 78149369945     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.03.011     Document Type: Review

References (9)

1. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
2. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
3. Pinsky P.F., Andriole G.L., Kramer B.S., et al. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trail. J Urol 2005, 173:746-751.
4. Cooperberg M.F., Moul J.W., Carroll P.R. The changing face of prostate cancer. J Clin Oncol 2005, 23:8146-8151.
5. Iversen P., Johansson J.E., Lodding P., et al. Bicalutamide (150 mg) vs. placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median follow-up from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004, 172:1871-1876.
6. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate specific antigen screening: Estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 2003, 95:868-878.
7. Epstein J.L., Sanderson H., Carter H.B., et al. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005, 66:356.
8. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004, 350:2239-2246.
9. Thompson I.M., Ankerst D.P., Etzioni R., et al. It's time to abandon an upper limit of normal for prostate specific antigen: Assessing the risk of prostate cancer. J Urol 2008, 180:1219-1222.